Apricot Capital

Medical Cube is a one-stop big data service platform providing data, media info, and consulting services for the pharmaceutical industry.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China.

Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

GensKey is a genetic testing medical diagnostic service provider that applies high-throughput sequencing technology to pathogen diagnosis to solve a series of difficulties in the detection rate, timeliness and accuracy of pathogenic diagnosis, so that many patients with severe infections get timely and accurate. Diagnosis.

Shenqi Medical focuses on the research and manufacture of innovative medical devices. Shenqi Medical offers a comprehensive product portfolio providing solutions for cardiovascular, structural heart disease, and peripheral and neurovascular medical devices in China.

Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.

Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation MicroPort CardioFlow is dedicated to providing advanced minimally invasive therapies for structural heart diseases with its best-in-class capacities in R&D, manufacturing, marketing, and technical consulting services. We believe in “Focus, Innovation, and Globalization”, and in accordance, we place the utmost importance on saving and improving quality of life for patients. Consequently, we constantly strive to bring the most innovative valvular disease treatment solutions to patients while also operating on a global vision to provide all patients and physicians with world-leading products that are superior, reliable, yet affordable.

Yachuang Pharmaceuticals is an innovative pharmaceutical research and development company focusing on liver diseases such as NASH and HBV. Founder Dr. Xu has worked in multinational pharmaceutical companies such as Johnson & Johnson, with over 20 years of successful innovation and management of innovative drugs. experience.

SinoMab Bioscience is a biopharmaceutical company. They develop therapeutic antibodies for the treatment of life-threatening diseases. They treat rheumatoid arthritis, immunological diseases, and systemic lupus erythematosus.

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.

Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.

Bellen Chemistry is a premier provider of a variety of heterocycles. Our activity is focused on the design and development of novel molecules,6361413375267061158256368.jpgintermediates for the Chemical and Pharmaceutical industries. Bellen Chemistryhas a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, as we deliver unrivalled chemical innovation to our customers worldwide.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.